Scleroderma, Kartoniert / Broschiert

Klappentext

Preface.- . Foreword.- Section 1: Introduction. .- 1. Historical perspective of scleroderma.- Section 2: Epidemiology, Genetics and Classification. .- 2. Epidemiology, Environmental and Infectious Risk Factors.- 3. Influence of ethnicity and sex bias in systemic sclerosis.- 4. Genetic Factors.- 5. Classification and Disease Subsets in Clinical Practice.- 6. Clustering and evolving concepts for subclassification.- 7. The Clinical Aspects of Autoantibodies.- 8. Systemic sclerosis overlap syndromes.- 9. Juvenile Localized and Systemic Scleroderma.- 10. Morphea (Localized scleroderma).- Section 3: The Biological Basis of Systemic Sclerosis. .- 11. Scleroderma Mimics.- 12. Introduction: The Etiopathogenesis of Systemic Sclerosis - an Integrated Overview.- 13. Pathology of Systemic Sclerosis.- 14. Inflammation And Immunity In Systemic Sclerosis.- 15. Autoantibodies as Markers and Possible Mediators of Scleroderma Pathogenesis.- 16. Mechanisms of Vascular Disease.- 17. Biomarkers in Systemic Sclerosis.- 18. Cellular and molecular mechanisms of fibrosis in systemic sclerosis.- 19. Overview of Animal Models.- Section 4: Cardiovascular Manifestations and Management. .- 20. Overview of management and outcome assessment in systemic sclerosis.- 21. Raynaud's Phenomenon, Digital Ulcers and Nailfold Capillaroscopy.- 22. Renal crisis and other renal manifestations.- 23. Cardiac Involvement: Evaluation And Management.- Section 5: Pulmonary Manifestations and Management. .- 24. Overview of lung involvement.- 25. Clinical assessment of ILD.- 26. Lung Imaging Perspective in Scleroderma.- 27. Treatment of Interstitial Lung Disease in systemic sclerosis.- 28. Pathogenesis of Pulmonary Arterial Hypertension.- 29. Clinical Assessment of Pulmonary Hypertension.- 30. The management of pulmonary arterial hypertension in the setting of systemic sclerosis.- Section 6: Gastrointestinal Manifestations and Management. .- 31. Overview of gastrointestinal tract involvement.- 32. UpperGastrointestinal Tract: Manifestations of Systemic Sclerosis.- 33. Lower Gastrointestinal Tract Involvement: Understanding the Interplay of Motility, the Microbiome and Nutrition.- Section 7: Skin, Musculoskeletal and Other Complications. .- 34. Evaluation and Management of Skin Disease.- 35. Calcinosis.- 36. Tendons, Joints, and Bone.- 37. Skeletal Muscle Involvement.- 38. Cancer in Systemic Sclerosis.- 39. Overlooked Manifestations.- 40. Pregnancy.- 41. Vaccinations in Patients with Systemic Sclerosis.- Section 8: Management and Outcome Assessment.- 42. Management Of Progressive Skin Involvement In Diffuse Scleroderma.- 43. Hematopoietic stem cell transplantation.- 44. Immune targeted therapies in SSc..- 45. Physical and Occupational Therapy.- 46. Psychosocial Issues and Care for Patients with Systemic Sclerosis.- Section 9: Case Studies: Approach to Complex Clinical Problems. .- 47. Measuring Disease Activity and Outcomes in Clinical Trials.- 48. Evolving clinical trial design andinnovative approaches.- 49. Drug Development and Regulatory Considerations for Systemic Sclerosis Therapies.- 50. Managing the Ischemic Finger in Scleroderma.- 51. Scleroderma Renal Crisis: a case study.- 52. Rapid diffuse skin disease with progressive joint contractures.- 53. Management of the Scleroderma Patient with Pulmonary Arterial Hypertension Failing Initial Therapy.- 54. Pseudo-obstruction with malabsorption and malnutrition.- 55. Progressive Interstitial Lung Disease Non-Responsive to Immunosuppressive Therapy.- 56. Body Image Distress in Scleroderma.- 57. Managing Complicated Digital Ulcers.- 58. Lower Limb Ulceration.